

Evolva Biotech A/S under frivillig likvidation

Fruebjergvej 3, 2100 København Ø, Denmark

CVR no. 25 53 25 38

Annual report 2020

Approved at the Company's annual general meeting on 15 July 2021

Chair of the meeting:





Contents

Statement by the liquidator	2
Independent auditor's report	3
Liquidator's review	5
Financial statements 1 January - 31 December	7
Income statement	7
Balance sheet	8
Statement of changes in equity	9
Notes to the financial statements	10



Statement by the liquidator

Today, I have discussed and approved the annual report of Evolva Biotech A/S under frivillig likvidation for the financial year 1 January - 31 December 2020.

The annual report is prepared in accordance with the Danish Financial Statements Act.

In my opinion, the financial statements give a true and fair view of the financial position of the Company at 31 December 2020 and of the results of the Company's operations for the financial year 1 January - 31 December 2020.

Further, in my opinion, the Management's review gives a fair review of the matters discussed in the Management's review.

It is proposed to the annual general meeting that the financial statements for 2021 should not be audited.

I recommend that the annual report be approved at the annual general meeting.

Copenhagen, 15 July 2021
Liquidator:

A handwritten signature in black ink, which appears to read 'Carsten Däweritz'. The signature is written in a cursive style and is positioned above a horizontal dotted line.

Carsten Däweritz



Independent auditor's report

To the liquidator of Evolva Biotech A/S under frivillig likvidation

Opinion

We have audited the financial statements of Evolva Biotech A/S under frivillig likvidation for the financial year 1 January - 31 December 2020, which comprise income statement, balance sheet, statement of changes in equity and notes, including accounting policies. The financial statements are prepared in accordance with the Danish Financial Statements Act.

In our opinion, the financial statements give a true and fair view of the financial position of the Company at 31 December 2020 and of the results of the Company's operations for the financial year 1 January - 31 December 2020 in accordance with the Danish Financial Statements Act.

Basis for opinion

We conducted our audit in accordance with International Standards on Auditing (ISAs) and the additional requirements applicable in Denmark. Our responsibilities under those standards and requirements are further described in the "Auditor's responsibilities for the audit of the financial statements" section of our report. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Independence

We are independent of the Company in accordance with the International Ethics Standards Board for Accountants' Code of Ethics for Professional Accountants (IESBA Code) and the additional requirements applicable in Denmark, and we have fulfilled our other ethical responsibilities in accordance with these rules and requirements.

Emphasis of matter in the financial statements

We wish to draw attention to note 1 to the financial statements, which describes the accounting policies applied by the Company. The financial statements are prepared for purposes of the Company's liquidation. Consequently, the financial statements may be unsuitable for other purposes.

We have not modified our opinion in respect of this matter.

Liquidator's responsibilities for the financial statements

Liquidator is responsible for the preparation of financial statements that give a true and fair view in accordance with the Danish Financial Statements Act and for such internal control as Liquidator determines is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, Management is responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting in preparing the financial statements unless liquidator either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

Auditor's responsibilities for the audit of the financial statements

Our objectives are to obtain reasonable assurance as to whether the financial statements as a whole are free from material misstatement, whether due to fraud or error and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs and the additional requirements applicable in Denmark will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of the financial statements.

As part of an audit conducted in accordance with ISAs and the additional requirements applicable in Denmark, we exercise professional judgement and maintain professional scepticism throughout the audit. We also:

Independent auditor's report

- ▶ Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error as fraud may involve collusion, forgery, intentional omissions, misrepresentations or the override of internal control.
- ▶ Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control.
- ▶ Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by liquidator.
- ▶ Conclude on the appropriateness of liquidator's use of the going concern basis of accounting in preparing the financial statements and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- ▶ Evaluate the overall presentation, structure and contents of the financial statements, including the note disclosures, and whether the financial statements represent the underlying transactions and events in a manner that gives a true and fair view.

We communicate with liquidator regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

Statement on the liquidator's review

The liquidator is responsible for the liquidator's review.


Our opinion on the financial statements does not cover the Management's review, and we do not express any form of assurance conclusion thereon.

In connection with our audit of the financial statements, our responsibility is to read the Management's review and, in doing so, consider whether the Management's review is materially inconsistent with the financial statements or our knowledge obtained during the audit, or otherwise appears to be materially misstated.


Moreover, it is our responsibility to consider whether the Management's review provides the information required under the Danish Financial Statements Act.

Based on the work we have performed, we conclude that the Management's review is in accordance with the financial statements and has been prepared in accordance with the requirements of the Danish Financial Statement Act. We did not identify any material misstatement of the Management's review.

Copenhagen, 15 July 2021
EY Godkendt Revisionspartnerselskab
CVR no. 30 70 02 28



Christian Schwenn Johansen
State Authorised Public Accountant
mne33234



Anders Roe Eriksen
State Authorised Public Accountant
mne46667



Liquidator's review

Company details

Name	Evolve Biotech A/S under frivillig likvidation
Address, Postal code, City	Fruebjergvej 3, 2100 København Ø, Denmark
CVR no.	25 53 25 38
Registered office	Copenhagen
Financial year	1 January - 31 December
Liquidator	Carsten Däweritz
Auditors	EY Godkendt Revisionspartnerselskab Dirch Passers Allé 36, P.O. Box 250, 2000 Frederiksberg, Denmark
Bankers	Danske Bank, Holmens Kanal 2, 1090 Copenhagen, Denmark



Liquidator's review

Business review

The Company's purpose is to carry on research and development, manufacturing and sales of ingredients and processes related to food, nutrition and personal care and to provide services to companies in Denmark and abroad as well as other related activities.

On 30 August 2017, Evolva Holding AG announced to the public that the Evolva Group would undertake a major site consolidation of its research and development activities in the remaining months of 2017.

As a result of this consolidation, all R&D activities in Evolva Biotech A/S have either been terminated or transferred to Evolva SA in Reinach Switzerland as of 31 December 2020.

Unusual matters having affected the financial statements

Going concern

As of 31 December 2020, the Company completed the transfer of all its activities to the Parent Company, Evolva SA, as part of the group-wide consolidation of the research and development activities in Reinach, Switzerland.

As a consequence of the transfer of activities, it is Management's intention is to liquidate the Company in the nearest future.

Since the Company is dormant in 2020, COVID-19 did not have any impact on the Company's operations.

Financial review

The income statement for 2020 shows a loss of DKK 196,806 against a loss of DKK 187,015 last year, and the balance sheet at 31 December 2020 shows equity of DKK 6,378,584.

At the general meeting on 21 January 2020, it was decided to initiate a voluntary liquidation. The decision was made on the basis of the group-wide consolidation of activities.

Due to the decision to liquidate the Company, all assets and liabilities are recognised at net realisable value.

Events after the balance sheet date

No events materially affecting the Company's financial position have occurred subsequent to the financial year-end.



Financial statements 1 January - 31 December

Income statement

Note	DKK	2020	2019
	Gross profit/loss	-116,208	638,876
3	Staff costs	-224	-838,574
	Profit/loss before net financials	-116,432	-199,698
4	Financial income	36,772	74,938
5	Financial expenses	-117,146	-62,255
	Profit/loss before tax	-196,806	-187,015
	Tax for the year	0	0
	Profit/loss for the year	-196,806	-187,015
	Recommended appropriation of profit/loss		
	Retained earnings/accumulated loss	-196,806	-187,015
		-196,806	-187,015



Financial statements 1 January - 31 December

Balance sheet

Note	DKK	<u>2020</u>	<u>2019</u>
	ASSETS		
	Non-fixed assets		
	Receivables		
	Receivables from group entities	6,364,290	5,371,819
	Other receivables	16,645	15,925
	Prepayments	4,750	0
		<u>6,385,685</u>	<u>5,387,744</u>
	Cash	100,171	1,189,922
	Total non-fixed assets	<u>6,485,856</u>	<u>6,577,666</u>
	TOTAL ASSETS	<u>6,485,856</u>	<u>6,577,666</u>
	EQUITY AND LIABILITIES		
	Equity		
6	Share capital	4,311,583	4,311,583
	Retained earnings	<u>2,067,001</u>	<u>2,263,807</u>
	Total equity	<u>6,378,584</u>	<u>6,575,390</u>
	Liabilities other than provisions		
	Current liabilities other than provisions		
	Trade payables	105,000	0
7	Other payables	2,272	2,276
		<u>107,272</u>	<u>2,276</u>
		<u>107,272</u>	<u>2,276</u>
	TOTAL EQUITY AND LIABILITIES	<u>6,485,856</u>	<u>6,577,666</u>

1 Accounting policies

2 Going concern uncertainties

8 Related parties



Financial statements 1 January - 31 December

Statement of changes in equity

DKK	Share capital	Retained earnings	Total
Equity at 1 January 2019	4,311,583	2,450,822	6,762,405
Transfer through appropriation of loss	0	-187,015	-187,015
Equity at 1 January 2020	4,311,583	2,263,807	6,575,390
Transfer through appropriation of loss	0	-196,806	-196,806
Equity at 31 December 2020	4,311,583	2,067,001	6,378,584



Financial statements 1 January - 31 December

Notes to the financial statements

1 Accounting policies

The annual report of Evolva Biotech A/S under frivillig likvidation for 2020 has been prepared in accordance with the provisions in the Danish Financial Statements Act applying to reporting class B entities and elective choice of certain provisions applying to reporting class C entities with the necessary adjustments due to the Company currently undergoing liquidation. Further reference is made to note 2.

The accounting policies used in the preparation of the financial statements have not been impacted by the restructuring and closedown of activities in the year why they are consistent with those of last year.

Reporting currency

The financial statements are presented in Danish kroner (DKK).

Foreign currency translation

On initial recognition, transactions denominated in foreign currencies are translated at the exchange rate at the transaction date. Foreign exchange differences arising between the exchange rates at the transaction date and the date of payment are recognised in the income statement as financial income or financial expenses.

Receivables and payables and other monetary items denominated in foreign currencies are translated at the exchange rate at the balance sheet date. The difference between the exchange rates at the balance sheet date and the date at which the receivable or payable arose or was recognised in the most recent financial statements is recognised in the income statement as financial income or financial expenses.

Public grants

Public grants to cover expenses are recognised in the income statement when it is deemed likely that all grant criteria have been met. Grants which must be repaid under certain circumstances are recognised only where they are not expected to be repaid.

Income statement

Revenue

The Company has chosen IAS 18 as interpretation for revenue recognition.

Revenue comprises fees from collaboration partners and group entities for the performance of research and development activities. Revenue is recognised in the income statement if the general recognition criteria are met, implying that the services concerned have been provided and that the amount can be measured reliably and is expected to be received. Revenue is recognised in accordance with the terms and conditions set out in the collaboration agreements. VAT, indirect taxes and discounts are excluded from revenue.

Gross profit/loss

The items revenue and external expenses have been aggregated into one item in the income statement called gross profit/loss in accordance with section 32 of the Danish Financial Statements Act.

Other operating income and operating expenses

Other operating income and operating expenses comprise items of a secondary nature relative to the Company's core activities, including gains or losses on the sale of fixed assets.



Financial statements 1 January - 31 December

Notes to the financial statements

1 Accounting policies (continued)

Other external expenses

Other external expenses include expenses related to lab operations, administration and premises, etc.

Staff costs

Staff costs include wages and salaries, including compensated absence and pension to the Company's employees, as well as other social security contributions, etc. The item is net of refunds from public authorities.

Financial income and expenses

Financial income and expenses are recognised in the income statement at the amounts that concern the financial year. Net financials include interest income and expenses as well as exchange rate adjustments.

Tax

Tax for the year includes current tax on the year's expected taxable income and the year's deferred tax adjustments. The portion of the tax for the year that relates to the profit/loss for the year is recognised in the income statement, whereas the portion that relates to transactions taken to equity is recognised in equity.

Balance sheet

Receivables

Receivables are measured at amortised cost, which usually corresponds to the nominal value. Provisions are made for bad debts on the basis of objective evidence that a receivable or a group of receivables is impaired. If the net realisable value is lower than the carrying amount, the carrying amount is reduced to such lower value.

The Company has chosen IAS 39 as interpretation for impairment of financial receivables.

Receivables with no objective evidence of individual impairment are tested for objective evidence of impairment on a portfolio basis. The portfolios are primarily composed on the basis of debtors' domicile and credit ratings in accordance with the Company's risk management policy. The objective indicators used for portfolios are determined based on historical loss experience.

Prepayments

Prepayments recognised under 'Assets' comprise prepaid expenses regarding subsequent financial reporting years.



Financial statements 1 January - 31 December

Notes to the financial statements

1 Accounting policies (continued)

Cash

Cash comprise cash and bank balances subject only to minor risks of changes in value.

Income taxes

Current tax payables and receivables are recognised in the balance sheet as the estimated income tax charge for the year, adjusted for prior-year taxes and tax paid on account.

Provisions for deferred tax are calculated, based on the liability method, of all temporary differences between carrying amounts and tax values, with the exception of temporary differences occurring at the time of acquisition of assets and liabilities neither affecting the results of operations nor the taxable income.

Deferred tax is measured according to the tax rules and at the tax rates applicable at the balance sheet date when the deferred tax is expected to crystallise as current tax. Deferred tax assets are recognised at the expected value of their utilisation; either as a set-off against tax on future income or as a set-off against deferred tax liabilities in the same legal tax entity. Changes in deferred tax due to changes in the tax rate are recognised in the income statement.

In the course of conducting business, tax and transfer pricing disputes with tax authorities may occur. Management judgement is applied to assess the possible outcome of such disputes. The 'most probable outcome' method is applied when making provisions for uncertain tax positions, and Management considers the provisions made to be adequate.

However, the actual obligation may deviate and depends on the result of litigation and settlements with the relevant tax authorities.

Liabilities

Other liabilities are measured at net realisable value.



Financial statements 1 January - 31 December

Notes to the financial statements

2 Going concern uncertainties

As of 31 December 2020, the Company completed the transfer of all its activities to the Parent Company, Evolva SA, as part of the group-wide consolidation of the research and development activities in Reinach, Switzerland.

As a consequence of the transfer of activities, it is Management's intention is to liquidate the Company in the nearest future.

DKK	2020	2019
3 Staff costs		
Wages/salaries	0	768,934
Pensions	0	54,298
Other social security costs	224	7,942
Other staff costs	0	7,400
	<u>224</u>	<u>838,574</u>
Average number of full-time employees	<u>0</u>	<u>1</u>
4 Financial income		
Exchange gains	<u>36,772</u>	<u>74,938</u>
	<u>36,772</u>	<u>74,938</u>
5 Financial expenses		
Other interest expenses	9,996	6,189
Exchange losses	<u>107,150</u>	<u>56,066</u>
	<u>117,146</u>	<u>62,255</u>
6 Share capital		
Analysis of the share capital:		
4,311,583 A shares of DKK 1.00 nominal value each	<u>4,311,583</u>	<u>4,311,583</u>
	<u>4,311,583</u>	<u>4,311,583</u>

The Company's share capital has remained DKK 4,311,583 over the past 5 years.



Financial statements 1 January - 31 December

Notes to the financial statements

DKK	2020	2019
7 Other payables		
Wages/salaries, salary taxes, social security contributions, etc.	2,272	2,272
Other accrued expenses	0	4
	<u>2,272</u>	<u>2,276</u>

8 Related parties

Information about consolidated financial statements

Parent	Domicile	Requisitioning of the parent company's consolidated financial statements
Evolve SA	Reinach, Switzerland	Available on the Company's website.

Related party transactions

Evolve Biotech A/S under frivillig likvidation was engaged in the below related party transactions:

DKK	2020	2019
Intercompany R&D fees from Evolve SA	0	51,006
Receivables from Evolve SA	5,693,454	4,631,002
Receivables from Evolve Inc.	670,836	740,817

Ownership

The following shareholders are registered in the Company's register of shareholders as holding minimum 5% of the votes or minimum 5% of the share capital:

Name	Domicile
Evolve SA	Reinach, Switzerland